Alvotech(ALVO) - 2023 Q4 - Annual Report

EXHIBIT 99.1 Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update Total Revenues in 2023 were $93.4 million, up 10$48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of$18.9 million, up by 37% from the same period last year Alvotech's Simlandi™ biosimilar to Humira (adalimumab) was approved in the U.S. as the first highconcentration biosimilar with interchangeable status Sales of Alvotech's Jamtek ...